Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 1 Subject Disposition
All eligible subjects were initially randomized to double-blind atorvastatin 20 or 80 mg once daily. After 4 weeks, subjects who tolerated atorvastatin therapy and achieved low-density lipoprotein cholesterol levels of  115 mg/dl were then randomized to concomitant administration of darapladib 40 mg, 80 mg, 160 mg, or placebo once daily for 12 weeks. The number of subjects and reason for discontinuation are depicted in this figure.
|
